Observational studyOpen heart2020
Impact of beta blockers on patients undergoing transcatheter aortic valve replacement: the OCEAN-TAVI registry.
Observational study in Open heart, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05721170 (Impact of Beta-blockers Among Patients Undergoing TAVI), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Beta-blockers Among Patients Undergoing TAVI: a Randomized Multicenter Trial
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper.ESC heart failure · 2026Review
- Age, creatinine, and ejection fraction score is a risk factor for acute kidney injury after surgical aortic valve replacement.Renal failure · 2025Article
- Calcium channel blocker use and outcomes following transcatheter aortic valve intervention for aortic stenosis.Cardiovascular intervention and therapeutics · 2025Observational
- Pre-Existing Left Bundle Branch Block and Clinical Outcomes After Transcatheter Aortic Valve Replacement.JACC. Asia · 2024Article
- Determinants and treatments of heart failure after transcatheter aortic valve implantation: moving up a notch.ESC heart failure · 2023Review
- Contemporary issues and lifetime management in patients underwent transcatheter aortic valve replacement.Cardiovascular intervention and therapeutics · 2023Review
- Effect of β-blocker on patients with moderate functional mitral regurgitation undergoing surgical aortic valve replacement.ESC heart failure · 2022Article
- Comparison of long-term mortality in patients who underwent transcatheter aortic valve replacement with or without anti-atherosclerotic therapy.Heart and vessels · 2021Article
- Inadequate Cardiac Unloading Following Transcatheter Aortic Valve Replacement.Circulation reports · 2021Article
- Small Left Ventricle and Clinical Outcomes After Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is paucity of data on optimal medical treatment, including use of beta blockers for patients undergoing transcatheter aortic valve replacement (TAVR). The study aimed to investigate the association of beta blockers and clinical outcomes following TAVR.
methodsWe examined data of 2563 patients who underwent TAVR between October 2013 and May 2017 obtained from a prospective multicentre cohort registry, the optimised catheter valvular intervention-TAVI registry. We compared the 2-year cardiovascular and non-cardiovascular mortality and in-hospital outcomes between patients with and without preprocedural beta-blocker administration by propensity score matching (PSM).
resultsPreprocedural beta blockers were prescribed in 867 patients (33.8%). After PSM, the incidence of in-hospital congestive heart failure was significantly lower in patients with preprocedural beta blocker (p=0.046). No differences were found in 2-year cardiovascular and non-cardiovascular mortality. In the subgroup analyses, beta-blocker administration was associated with a lower cardiovascular mortality within 2 years in patients with a history of coronary artery bypass grafting (CABG; log-rank p=0.017), presence of peripheral artery disease (PAD; log-rank p=0.003) and brain natriuretic peptide (BNP) ≥400 pg/mL (log-rank p=0.003). When stratified by postprocedural left ventricular ejection fraction (post-LVEF), beta-blocker administration was associated with a lower cardiovascular mortality among patients with post-LVEF <50% (log-rank p=0.024).
conclusionsPreprocedural beta-blocker administration was not associated with 2-year cardiovascular and non-cardiovascular mortality in overall, but was associated with a lower 2-year cardiovascular mortality in patients with a history of CABG, presence of PAD, BNP ≥400 pg/mL and post-LVEF <50%. The findings must be validated using randomised trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.